- Patient Preparation
- Actively growing isolate in pure culture.
- Specimen Preparation
- Transport sealed container with pure culture on solid or liquid media. Place each specimen in an individually sealed bag.
- Storage/Transport Temperature
- Room temperature. If culture is suspected of being a microorganism listed as infectious substance affecting humans on IATA list, submit specimen according to Biological Substance,
Submit specimen according to Infectious Substance, Category A, shipping guidelines.
- Unacceptable Conditions
- Mixed cultures or non-viable organisms. Organisms submitted on an agar plate.
- Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks
|Available Separately||Test Name||Methodology||Reference Interval/Drugs Tested||CPT Code|
|Yes (0060347)||Antimicrobial Susceptibility - AFB/Mycobacterium tuberculosis Primary Panel||MGIT960||The interpretation provided is based on results for the following drugs at the stated concentrations:|
Drugs tested: Ethambutol: 5.0 µg/mL; Isoniazid: 0.1 µg/mL (0.4 µg/mL if resistant to 0.1 µg/mL); Pyrazinamide: 100 µg/mL; Rifampin: 1.0 µg/mL.
This procedure screens isolates of M. tuberculosis complex for drug resistance. The procedure does not use serial dilutions to provide quantitative MIC values. Single critical concentrations for each antimycobacterial agent used have been defined by the United States Public Health Service.
|No||Antimicrobial Susceptibility - AFB/Mycobacterium tuberculosis Secondary Panel||Agar proportion |
and Broth dilution
|Effective February 21, 2012|
Note: If M. tuberculosis isolate is resistant to rifampin or any two primary drugs, a secondary panel will be performed as a send-out test. The interpretation provided is based on testing for the following drugs at the stated concentrations:
Drugs tested: Amikacin: 6 µg/mL; capreomycin: 10 µg/mL; cycloserine: 60 µg/mL; ethionamide: 10 µg/mL; kanamycin: 6 µg/mL; PAS: 8 µg/mL; streptomycin at a low level (2.0 µg/mL) and a high level (4.0 µg/mL). Levofloxacin and moxifloxacin are tested at 2, 4 and 8 µg/mL
|87190 x6, 87188 x3|
|No||Antimicrobial Susceptibility - AFB/Mycobacteria||Broth Microdilution||See organism-specific panels below.||87186|
|No||Mycobacterium avium-intracellularae Complex||Broth Microdilution||Effective May 20, 2013|
Drugs tested: Amikacin, ciprofloxacin, clarithromycin, doxycycline, ethambutol, ethionamide, isoniazide, linezolid, moxifloxacin, rifabutin, rifampin streptomycin and trimethoprim/sulfamethoxazole (TMP/SXT).
Selective reporting by organism.
Clarithromycin, moxifloxacin and linezolid are the only drug for which CLSI provides interpretive guidelines. Clarithromycin results predict azithromycin. For drugs other than those listed above there are no CLSI interpretive guidelines; therefore, only MIC is reported. Because MIC results do not predict clinical response, rifampin, rifabutin, and ethambutol MICs are not reported.
|No||Rapid Growing Mycobacteria||Broth Microdilution||Effective May 20, 2013|
Drugs tested: Amikacin, amoxicillin/clavulanic acid, cefepime, cefoxitin, ceftriaxone, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin, tigecycline, tobramycin (M. chelonae only), and trimethoprim/sulfamethoxazole (TMP/SXT). Selective reporting by organism.
|No||Other Slowly-Growing |
|Broth Microdilution||Effective May 20, 2013|
Drugs tested: Amikacin, ciprofloxacin, clarithromycin, doxycycline, ethambutol, ethionamide, isoniazide, linezolid, moxifloxacin, rifabutin, rifampin, streptomycin and trimethoprim/sulfamethoxazole (TMP/SXT). Selective reporting by organism.
CLSI recommends that isolates of M. kansasii be tested against rifampin and clarithromycin only. Rifampin-susceptible isolates are also susceptible to rifabutin. If the isolate is rifampin-resistant, the following secondary drugs will also be reported: Amikacin, ciprofloxacin, ethambutol, linezolid, moxifloxacin, rifabutin, streptomycin and trimethoprim-sulfamethoxazole.
M. marinum isolates are tested against amikacin, ciprofloxacin, clarithromycin, doxycycline, ethambutol, moxifloxacin, rifabutin, rifampin, and trimethoprim-sulfamethoxazole. Interpretation is based on CLSI guidelines.
Slowly-growing NTM other than M. kansasii and M. marinum are tested against amikacin, ciprofloxacin, clarithromycin, ethambutol, linezolid, moxifloxacin, rifabutin, rifampin, streptomycin, and trimethoprim-sulfamethoxazole.
Interpretive criteria are based on CLSI guidelines for M. kansasii..
See Compliance Statement B: www.aruplab.com/CS
|Component Test Code*||Component Chart Name|
- Acid Fast Bacilli
- AFB Susceptibility Panel
- Amikacin susceptibility
- Amoxicillin/clavulanic acid susceptibility
- Capreomycin susceptibility
- Cefepime susceptibility
- Cefoxitin susceptibility
- Ceftriaxone susceptibility
- Ciprofloxacin susceptibility
- Clarithromycin susceptibility
- Cycloserine susceptibility
- Doxycycline susceptibility
- Ethambutol susceptibility
- Ethionamide susceptibility
- Imipenem susceptibility
- Isoniazid susceptibility
- Kanamycin susceptibility
- Levofloxacin susceptibility
- Linezolid susceptibility
- Minocycline susceptibility
- Moxifloxacin susceptibility
- Mycobacterium tuberculosis susceptibility testing
- PAS susceptibility
- Pyrazinamide susceptibility
- Rapidly-Growing Mycobacterium species
- Rifabutin susceptibility
- Rifampin susceptibility
- Slow-Growing Mycobacterium species
- Streptomycin susceptibility
- Tigecycline susceptibility
- TMP/SXT susceptibility
- tobramycin (M. chelonae only) susceptibility
- Trimethoprim/sulfamethoxazole susceptibility